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There has been considerable recent progress in understanding of the mechan- 
isms involved in cooperation between T  and B  lymphocytes in the induction of 
humoral antibody formation (see for example 1), but much  still remains to be 
learned. The discovery of an interaction between lymphocytes and the fixed C3 
component of complement (2-5), and the demonstration by Nussenzweig et al. 
that C3 receptors are a  feature of B-cell populations (6-10), raise the possibility 
that  C3  might play a  part in  this process  (11).  Germinal centers of lymphoid 
tissue,  in  which  the  induction  of  antibody production  may  occur,  contain  B 
cells, fixed C3, and complexes capable of fixing C3 (12). I  have previously shown 
that  treatment  of mice in  vivo with  the  C3-cleaving protein  of cobra venom 
(CoF)  1 suppresses  thymus-dependent  but  not  thymus-independent  antibody 
production,  suggesting a  possible role for  C3  in lymphocyte cooperation  (11). 
Analogous results have been obtained in vitro (13). These results are extended 
in the present paper. 
Materials and Methods 
Animals.--Balb/c mice, bred in the Department of Pathology, University of Cambridge, 
7-12 wk of age and weighing 18-28 g were used throughout. 
Antisera.--Antimouse  C3 serum was raised in a Clun Forest sheep by a modification of the 
method of Mardiney and Mttller-Eberhard (14, 15). It was  monospecific for  C3. Anti-CoF 
sera were raised in Balb/c mice by injection of purified CoF emulsified in complete Freund's 
adjuvant, followed by booster doses of CoF in incomplete adjuvant. The sera were inactivated 
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(56°C,  30  min), absorbed with SRBC, and then concentrated 10-fold by salt precipitation 
before use in vivo. 
Measurement of Serum C3.--C3 was measured by electroimmunodiffusion (16). Conversion 
of C3 was assayed by antigen-antibody-crossed electrophoresis using anti-C3 in the second 
stage gel (17). 
Isolation  of CoF.--CoF was purified from Naja naja  venom  (Sigma  Chemical Co.,  St. 
Louis, Mo.) by the method of Ballow and Cochrane (18). Average yield from three different 
batches of crude venom was 6.75 mg of purified CoF/g of venom. In each case the CoF had an 
anticomplementary activity of 1 U/4.0-5.0 #g protein, was homogenous on analytical poly- 
acrylamide gel electrophoresis at an applied sample concentration of 250 #g/ml, and gave a 
single line on gel diffusion testing with antisera raised against it in mice and rabbits. 
Other C3-Reactive Agents.--Yeast cell walls were prepared from baker's yeast as described 
by Lachmann et al.  (19).  Human IgG (HGG) was isolated from normal serum by salt pre- 
cipitation and exclusion from DEAE-cellulose in 0.01 M phosphate buffer pH 8.0. It was ag- 
gregated by incubating a  solution in phosphate-buffered saline  (PBS)  of 4.0  mg/ml for 10 
min at 63°C. IgG1 was isolated from monospecific sheep antimouse C3 serum by salt precipita- 
tion and chromatography on DEAE-cellulose in 0.01 M Tris-phosphate buffer pH 8.0. Purified 
type III pneumococcal polysaccharide (SSSIII) was obtained from Welcome Reagents Ltd., 
Beckenham, Kent, England. 
Antigens.--SRBC  from the same sheep were used throughout. Blood  was drawn weekly 
into acidified  citrate dextrose, stored at  4°C,  and washed three times with PBS before use. 
Ovalbumin  (OA)  (twice crystallized)  (Koch-Light Laboratories Ltd.,  Colnbrook, England) 
was absorbed onto nascent alumina at pH 6.5. HGG solution (Batch C-717, American Cyana- 
mide Co., Lederle Laboratories Div., Pear River, N. Y.). A saline was emulsified in Freund's in- 
complete adjuvant.  Polyvinylpyrrolidone with  an  average  mol wt  of  360,000  (PVP  360) 
(Sigma  Chemical Co.,  St. Louis, Mo.) was used in saline solution. 
Serum  Antibody  Titration.--Antibodies  were  detected by  direct agglutination  of  SRBC 
or passive agglutination of antigen-coated red cells.  Sera were titrated in microtiter plates 
(Cooke  Engineering Co.,  Alexander, Va.)  in  vol of 25  #1.  PBS,  or  PBS  containing 0.2% 
bovine serum albumin (PBS/BSA) when tanned cells were in use, was used as a diluent. 25 #1 
of indicator cells were added to each well and,  after thorough mixing on a  "Micromixer" 
(Taiyo Bussan Co., Tokyo, Japan), allowed to settle at room temperature in a moist chamber. 
All sera from each experiment were tested on the same occasion; the agglutination patterns 
and end-points were read "blind" by the same person throughout. The end-points in replicate 
titrations of the same sample did not differ from each other by more than one tube and were 
usually identical. 
Mercaptoethanol-Resistant Antibody.--The  direct method of Scott and  Gershon was used 
(20). Filtration of sera on Sephadex G200 (Pharmacia Fine Chemicals, Inc., Uppsala, Sweden) 
and antiglobulin testing of different fractions using specific antimouse # and 3, sera were un- 
dertaken to confirm that  mercaptoethanol-sensitive and resistant  antibody did correspond 
to IgM and IgG, respectively. 
Preparation of Indicator Cells.--SRBC were used at 1% in PBS. OA was coated onto tanned 
human 0 cells by incubation of equal volumes of 2% tanned cells and 5 mg/ml OA in PBS for 
30 min at room temperature. After washing and resuspension in PBS/BSA the cells were used 
at 2%. Tanned fresh human group O red cells were coated with PVP by the method of An- 
dersson (21). Equal  volumes of 2% tanned cells and 0.2  mg/ml polyvinylpyrrolidine with 
an average mol wt of 10,000 (PVP 10)  (Sigma Chemical Co.,  St. Louis, Mo.) were incubated 
together at room temperature for 10 min. After washing they were used at  1%. 
Immune Elimination  (22).--The antibody response to HGG was evaluated by following 
the whole body clearance of [125I]HGG as described elsewhere (23). 
Antigen-Specific Rosette-Forming Cells (RFC).--RFC in the spleens of mice were detected 128  ROLE  OF  COMPLEMENT IN  INDUCTION OF  ANTIBODY RESPONSE 
by a modification  of the method of McConnell  et al. (24), which detects only B-cell RFC 
especially in Balb/c mice (reference 25 and footnote 2). 
Experimental Deslgn.--The pattern of most of the experiments  designed to test the pos- 
sible effects of C3-reactive agents on antibody production in vivo was as follows. Balb/c mice 
all of the same age and sex were subdivided into control and different test groups numbering 
from 8 to 12 in each. Mter being weighed they were all bled for control serum C3 levels and 
test groups  were given  CoF or other agents at different  times before  or after injection of 
antigen on day 0; controls received PBS at the same time. A total dose of 200 U of CoF/kg/ 
animal in four equally divided i.p. injections over 24 h was given (11, 26). In most experiments 
the mice were also bled again immediately before injection of antigen to obtain control serum 
antibody levels. Mter receiving antigen all the mice were bled at intervals during the period 
of the antibody response. 
Presentation of Data.--The results of antibody titrations are presented either in tabular 
form or graphically,  each point respresenting the arithmetic mean, with 95% confidence points, 
of the --logs titers of all the animals in each group on each day. 
Statistical Methods.--Data from test and control groups in each experiment were examined 
by analysis of variance and Bartlett's test for homogeneity of variance.  Significant contrasts 
between groups were detected by t tests, the value of t being computed from the residual varia- 
tion, and are indicated by P  values. 
RESULTS 
Primary  Anti-SRBC  Response.--The  primary  hemagglutinating  antibody 
response to SRBC, especially its IgG component, was significantly inhibited by 
pretreatment  of  mice  with  CoF,  particularly  when  the  period  of  maximal 
plasma C3 depletion produced by CoF was between days 2-4 after injection of 
the antigen  (11)  (Fig. 1). This effect was the same irrespective of  the dose of 
CoF,  between  100-500  U/kg/animal,  or  the  route  of  administration,  i.v.  or 
i.p., of the SRBC  (14). 
Secondary  Anti-SRBC  Response.--The  secondary  response  to  SRBC  was 
suppressed by treatment of primed mice with CoF before the second injection of 
SRBC,  though  in  this  case  most  of the  antibody detected  was  IgG  in  both 
control and CoF-treated mice (Fig. 2). The secondary response  in mice whose 
primary response had  been  suppressed by  CoF was  delayed and  poorly sus- 
tained by comparison with control mice primed without  CoF treatment (Fig. 3). 
SRBC-RFC Response.--After i.p. injection of SRBC on day 0  there is a rapid 
increase in the number of specific SRBC-RFC in the  spleen between days 2-4. 
Pretreatment  of  mice  with  CoF  producing  maximal  systemic  C3  depletion 
during this period  suppressed the proliferation of RFC  (Fig. 4).  None  of the 
CoF-treated animals immunized with 2.5  X  l0  T SRBC produced any IgG anti- 
body, but the relative proportion  of RFC inhibited by class-specific antimouse 
# and 7 sera was the same as in control mice (14). 
Effect of Passive Anti-CoF Serum.--Injection of anti-CoF serum into mice  de- 
pleted of C3 by CoF caused a prompt rise in plasma C3. After an optimal dose  of 
anti-CoF, plasma C3 rose from less than  1% to 50% of normal in 15 h,  75%  at 
24 h, and 100% or more by 48 h  (14). The effects of such a dose of anti-CoF on 
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FIG. 1.  Effect of CoF on the total and  mercaptoethanol-resistant anti-SRBC response. 
CoF was given to the test animals so as to produce maximal depletion of circulating C3 be- 
tween 2-4 days after i.p. injection of 2.5  >( 10  s SRBC. Above, total antibody titers; below, 
mercaptoethanol-resistant antibody titers,  x, controls treated  with  PBS; ©,  CoF-treated 
mice; T, i.p. injection. 
the suppressive action  of CoF are shown in Fig.  5.  Injection of anti-CoF  on 
either day 0 or day  2 which restored to normal, or at least appreciably raised 
C3 levels between  days 2 and 4, permitted a normal anti-SRBC response to be 
mounted. When anti-CoF was given on day 4 the response was suppressed until 
then, but subsequently reached normal levels with a delay of 2 days. Anti-CoF 
enabled CoF-treated mice to produce IgG antibody. Furthermore, in the day 8 
sera of mice given anti-CoF on day 4 virtually all the antibody was IgG, mean 
titer -4- SD equals 6.8 ±  0.6, whereas in the normal control mice the IgG anti- 
SRBC titer was only 3.6 ±  2.6 (P <  0.001). 
Anti-CoF serum had no effect on the anti-SRBC response in mice not treated 
with CoF. As a further control, normal serum which had been inactivated, ab- 
sorbed, and concentrated in parallel with the anti-CoF serum had no effect on 130  ROLE  OF  COMPLEMENT  IN  INDUCTION  OF  ANTIBODY  RESPONSE 
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Fro. 2.  Effect of CoF on the secondary anti-SRBC response. Groups of mice were primed 
by i.p. injection of either 2.5  X  10  8 SRBC 6 mo previously (above) or 2.5 X  10  7 SRBC  3  wk 
previously (below). CoF was given so as to produce maximal depletion of circulating C3 2-4 
days after a  secondary i.p.  injection of 2.5  X  10  8 SRBC.  x, controls  treated with PBS;  ©, 
CoF-treated mice; and  T, i.p. injection. 
either the control anti-SRBC response or the suppression of that response by 
CoF. 
A low dose of anti-CoF, which enabled plasma C3 levels in CoF-treated mice 
to rise  almost as rapidly as  an optimal dose,  was,  however, less  effective in 
abrogating  the  suppressive  effect of  CoF  on  the  anti-SRBC  response  (14). 
This may be due to the fact that  although  even trace amounts of anti-CoF 
antibody in vivo can clear circulating CoF and permit plasma C3 levels to rise 
(14), relatively high concentrations of anti-CoF antibody are required to inhibit 
C3 cleavage by CoF (Fig. 6). 
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FIG. 3.  Effect of CoF on induction  of immunological memory. Two groups of mice were 
each given an i.p. injection of 2.5  X  l0  s SRBC 6 mo after priming with 2.5  X  108 SRBC. 
×, control mice treated with  PBS before priming;  O, test mice treated with  CoF so as to 
produce maximal depletion  of circulating C3 2-4 days after priming 6 mo previously; and 
T, i.p.  injection.  Above, total antibody titers;  below, mercaptoethanol-resistant  antibody 
titers. 
CoF in  adjuvant  contained high levels of anti-CoF  antibodies  which blocked 
in vitro C3 cleavage by CoF, whereas the sera of mice immunized with CoF in 
saline did not (Fig. 6). In neither group did CoF lower plasma C3 in vivo. The 
anti-SRBC response was unaffected by CoF in mice whose sera inhibited CoF in 
vitro, while in mice whose sera failed to inhibit it the anti-SRBC response was 
suppressed by CoF (Table I). 
Effect o/Other C3-Reactive A gents.--Zymosan  (yeast cell walls),  heat-aggre- 
gated HGG, the IgG1 fraction of monospecific sheep antimouse C3 serum and 
SSSIII all interact  with  C3 in various ways (27,  28). None of them produced 
more than a  transient  lowering of plasma C3 in vivo, but they all caused sig- 10  4 
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FIG. 4.  Effect of CoF on the RFC response to SRBC. Mice were given an i.p. injection of 
2.5  X  l0  T SRBC on day 0. Each point represents the geometric mean of four mice on each 
day. x, controls treated with PBS; and O, CoF-treated mice  (confidence limits not shown). 
nificant suppression of the anti-SRBC response (Table II). PVP 360 resembles 
SSSIII in being a  high molecular weight,  nonbiodegradable polymer which  is 
itself a  thymus-independent antigen (29);  but unlike SSSIII  it had  no effect 
either  on C3  in normal murine serum in vitro  (Fig.  7)  or  on the  anti-SRBC 
response in vivo (Table III). 
Primary Response to Protein Antigens.--The  onset  of  antibody production 
after immunization with OA was delayed for about 2 days by CoF, irrespective 
of whether it was given so as to maximally deplete C3 between days 0-2, 2-4, 
or  4-6  (Fig.  8).  The  immune elimination of  [125I]HGG  was  significantly re- 
FIG. 5.  Effect  of passive anti-CoF serum on suppression of the anti-SRBC response  by 
CoF. Mice were given either CoF or PBS before i.p. injection of 2.5 X  107 SRBC on day 0. 
Different groups of CoF-treated mice were then given 100 ~1 of mouse anti-CoF serum (10 X 
concentrated, absorbed with SRBC)  on day 0  (above), day 2  (middle), or day 4  (below). 
The effects on C3 levels (above in each section) and antibody titers (below in each section) 
are shown. Each point represents the mean with 95% confidence limits of either the serum C3 
level or the antibody titer. A, controls, treated with PBS; O, CoF-treated mice;  O, CoF- 
treated mice given anti-CoF on day 0; A, CoF-treated mice given anti-CoF on day 2;  D, 
CoF-treated mice given anti-CoF on day 4;  T, i.p. injection; and ,m, time during which 
serum C3 was  <5% of normal in mice treated with CoF but not anti-CoF. Significant dif- 
ferences  between the groups which received  CoF alone and those which received  CoF and 
anti-CoF are indicated by P  values. "6 
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133 Fla.  6.  Effect of anti-CoF antibodies on C3 cleavage by CoF in vitro. CoF  (5.0/zg)  or 
PBS  were  preincubated with  50  #1  vol  of  fresh  neat  mouse  anti-CoF  sera,  dilutions of 
these antisera in fresh normal mouse serum or normal mouse serum alone, before addition 
of EDTA to 0.01 M and an excess of native murine C3 (20 #1 of 10  >(  concentrated serum 
euglobulins).  After incubation at  37°C  the  C3  profile  was analyzed by  antigen-antibody- 
crossed electrophoresis. The two anti-CoF sera tested were pooled from mice immunized with 
either CoF in PBS ("weak" anti-CoF) or CoF in adjuvant  ("strong" anti-CoE). 1-5,  strong 
Anti-CoF; 7-10, weak anti-CoF;  1 and  7,  no CoF, PBS controls; 6,  no anti-CoF, normal 
serum control; 2 and 8, neat anti-CoF; 3 and 9, ~  anti-CoF; 4 and 10, ~  anti-CoF; and 5, 
anti-CoF. 
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TABLE  I 
Eff~t ~  Ac~elmmunityto CoF on Suppression ~  ~eAn~SRBC Responseby CoF 
Agglutination tlter§ 
Immunization*  Pretreat-  ment:~  Day 4  Day 6  Day 8 
To~l  IgG  To~l  IgG  To~i  IgG 
2>(10/zgCoF  PBS  7.64-0.5  3.64-0.8  7.34-0.5  6.14-0.4  7.44-0.5  6.14-0.4 
in PBS 
2X10b~gCoF  CoF  0.44-0.7  0  5.54-1.1  1.14-2.1  4.64-1.3  1.0-t-  1.9 
in PBS  P  <  0.001  P  <  0.001  P  <  0.001  P  <  0.001  P  <  0.001  P  <  0.001 
20/~g CoF in 
FCA 
20 ttg CoF in 
FICA 
CoF  7.6 4- 0.5  5.7 4- 0.8  7.6 4- 0.8  6.3 4-  1.0  8.3 -4-  1.0  6.94-4-  0.7 
* Groups of eight mice were each immunized by i.p. injections of CoF in the doses shown, the last injection being 
4 wk before the start of this experiment. 
~t 4 i.p. injections of either 5.0/~g each of CoF or of PBS alone were given during the 24 h preceding i.p. injection 
of 2.5 X 10s SRBC on day 0. 
§ Mean --log~  titer -4- SD of all the mice in each group. Significant differences  from the control, PBS pretreated,  group 
are shown by P values. 
TABLE  II 
Effect of C3-Reactive Agents on the A nti-S  RB C Response 
Agglutination  titer:~ 
Pretreatment*  Day 4  Day 6 
Total  IgG  Total  IgG 
PBS  7.6  4-  0.5  3.8  4-  1.4  7.9  4-  0.6  7.5  -4-  0.5 
CoF  1.9  -4-  1.1  0.1  4-  0.4  3.8  4-  2.7  1.4  4-  2.6 
P  <  0.001  P  <  0.001  P  <  0.00l  P  <  0.001 
Zymosan  6.2  4-  1.0  2.2  4-  0.7  7.1  4-  0.9  5.9  4-  2.4 
P  <  0.05  P  <  0.001 
Aggregated HGG  4.1  4-  1.5  1.8  4-  1.0  6.6  4-  0.5  5.9  4-  2.3 
P  <  0.001  P  <  0.001  P  <  0.05 
Anti-C3 IgG  4.0  4-  1.4  1.3  -4-  0.9  6.3  4-  0.7  5.0  4-  2.6 
P  <  0.001  P  <  0.001  P  <  0.05  P  <  0.05 
SSSIII  2.4  4-  1.5  0.4  4-  0.5  6.0  4-  1.1  3.6  4-  3.2 
P  <  0.001  P  <  0.001  P  <  0.01  P  <  0.01 
* Groups of eight mice were each given four i.p. injections during the 24 h  preceding i.p. 
injection of 2.5  X  10  s SRBC on day 0. The doses of each agent were as follows: CoF, 4  X  5.0 
/~g;  zymosan, 4  X  0.75 mg; aggregated HGG,  4  X  10 mg; anti-C3 IgG, 4  ×  0.5  mg; and 
SSSIII, 4  ×  5.0/zg. 
Mean  --log~ agglutination titers  -4-  SD  of  all the animals in each group.  Significant 
differences from the control, PBS pretreated, group are shown by P  values. 136  ROLE  OF  COMPLEMENT  IN  INDUCTION  OF  ANTIBODY  RESPONSE 
Fio. 7.  Effect of thymus-independent  antigens on C3 in normal mouse serum. SSSIII and 
PVP 360 in a concentration  of 5 #g/ml were incubated  for 1 h at 37°C with  fresh normal 
mouse serum. The C3 profiles were then analyzed by antigen-antibody-crossed electrophoresis. 
From above downwards; 1, SSSIII; 2, PVP 360; 3, PBS control; and 4, yeast cell walls control. 
The extent  of C3 conversion by PVP 360 did not differ from that  in PBS control,  while 
SSSIII had the same effect as the yeast cell walls. 
tarded in mice treated with CoF before immunization with HGG (Fig. 9). OA 
and HGG are both thymus-dependent antigens (30, 31). 
Primary Response to PVP.--CoF had no effect on the response to the thymus- 
independent antigen PVP 360 (29),  irrespective of the relative timing of injec- 
tions of CoF and antigen (Fig.  10). 
DISCUSSION 
The  present  observations  confirm  that  CoF  suppresses  thymus-dependent 
antibody production,  particularly  the relatively more thymus-dependent  IgG 
component of the  anti-SRBC  response  (32,  33),  but not  thymus-independent 
responses (11). The inhibition by CoF of proliferation of specific RFC (B cells) 
suggests that it acts at an early phase of the allergic response. M.  B.  PEPYS 
TABLE III 
Effects of SSSIII and PVP on the Anti-SRBC Response 
137 
Agglutination titer~t 
Pretreatment*  Day 4  Day 6  Day 8 
Total  IgG  Total  IgG  Total  IgG 
PBS  5.9  -4-  1.7  0  5.4  -4-  1.3  4.3  ~  3.0  4.7  -4- 2.1  3.7  -4- 2.8 
PVP 360  6.3  -4-  1.4  0  5.9  -4-  1.0  3.4  ~  2.9  5.4  -4-  1.3  2.8  -4- 3.0 
SSSIII  2.6  4-  2.1  0  4.0  -4-  1.9  0.1  :k  0.4  2.6  +  2.4  0 
P  < 0.001  P  <  0.01  P  <  0.01 
* Groups of eight mice were each given four i.p. injections during the 24 h preceding i.p. 
injection of 2.5  X  108 SRBC on day 0. The doses of each agent were as follows: PVP 360, 
4 )< 5.0 #g; and SSSIII, 4 X 5.0 #g. 
Mean --log2 agglutination titer  -4- SD of all the animals in each group. Significant dif- 
ferences from the control, PBS pretreated, group are shown by P values. 
The possibility that the effects of CoF on induction of antibody production 
were due to some other mechanism than complement depletion must be con- 
sidered. In the doses used CoF was nontoxic in vivo (14, 26) and it had no cyto- 
toxic action on cultured  murine spleen cells during 48 h  in vitro? That  CoF 
suppressed  secondary  as  well  as  primary responses  argues  against  antigenic 
competition as a possible mode of action, since competition is a feature only of 
primary responses (34,  35). In mice suitably preimmunized with CoF its sup- 
pressive effect on antibody production was prevented, whereas previous active 
immunization  with  the  dominant  antigen  of  a  competing pair  generally en- 
hances rather than abolishes subsequent competition (35). Thymus-independ- 
ent  antigens  do  not  cause  antigenic  competition  of  the  thymus-dependent 
sequential type under consideration here (35), but SSSIII, which activates C3, 
inhibited particularly the IgG component of the anti-SRBC response. In con- 
trast another thymus-independent antigen, PVP,  which does not activate C3, 
had no effect. 
Diverse agents which all interact with C3 : yeast cell walls, aggregated HGG, 
SSSIII, and anti-C3 antibodies, also suppressed the anti-SRBC response. None 
of these agents produced sustained systemic C3 depletion, and CoF itself is still 
able  to  suppress  antibody production  in  animals  protected  from plasma  C3 
depletion  by low levels of anti-CoF  antibodies  which  do not  inhibit  its  C3- 
cleaving action. It is, therefore, likely that if C3 does have a role in the induc- 
tion of antibody production then this is played out in the peripheral lymphoid 
organs. This suggestion is supported by the specific localization of [125I]COF in 
the spleens of mice with circulating anti-CoF antibodies (14). 
The effects on antibody responses might result from complement activation 
3 G. Janossy, personal communication. I0- 
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rather than interference with direct participation of complement in induction. 
For example C3 fragments can suppress in vitro antigen-induced lymphocyte 
transformation.  4 However,  the  inhibition  by  isolated  anti-C3  antibodies  of 
thymus-dependent antibody responses which has been observed in vitro (13) 
cannot be attributed to the generation of C3 fragments. It seems more likely 
that the various C3-reactive agents act by reducing functional complement at 
the site of induction of antibody procluction. 
C5- and C6-deficient animals mount normal antibody responses (36), which, 
in conjunction with the observed effects of anti-C3 antibodies, indicates that C3 
is the important component. C4-deficient guinea pigs, although they can still fix 
C3 by the alternate pathway, have impaired responses to certain antigens (37). 
The present in vivo results,  and other in vitro data (13),  suggest that C3 
plays a part in induction of thymus-dependent antibody production, and may, 
therefore, participate in lymphocyte cooperation. Thymus-dependent presen- 
tation of antigen to B cells at the surface of macrophages has been suggested in 
several  hypotheses  (38,  39)  and  there  is  evidence  that  B  cells  undergoing 
activation to transform and secrete antibody, both in vivo and in vitro, tend 
to be aligned on the surface of, or clustered around macrophages (40-43).  In 
in  vitro  studies  with  separated  cell  populations  Feldmann has  shown  that 
activated T cells are stimulated by antigen to secrete a specific antigen-binding 
product (44). It is apparently a form of IgM which, in complexes with antigen, 
adheres to the surface of macrophages and leads to triggering of specific B cells 
to antibody formation (45, 46). 
It is postulated here that C3 may have a role in presentation of antigen to B 
cells,  by enhancing approximation of the different cell  types involved in co- 
operation.  Complexes  of  antigen,  either  with  the  putative  specific  T-cell 
product or with other immunoglobulin, could fix C3 and then bind to the sur- 
face of macrophages which bear a membrane receptor for fixed C3 (4). B cells 
would, by virtue of their C3 receptor, tend to adhere nonspecifically to macro- 
phages bearing C3-coated complexes, and if a B cell had the appropriate specific 
antigen receptors  it might then recognize the presented antigen and be trig- 
gered. It is relevant that while both IgG and IgM-antigen-C3 complexes bind 
to macrophages, only the IgM complexes are held on the cell surface and are not 
l Pepys, M. B., and A. E. Butterworth. 1974. Inhibition by C3 fragments  of C3-dependent 
rosette formation and  antigen-induced lymphocyte transformation. Clin. Exp.  Immunol. 
In press. 
FIG. 8. Effect of CoF on the antibody response to OA. CoF was given  to different  groups 
of mice  so as to produce  maximal  depletion  of circulating  C3 between  0--2 (above),  2-4 (middle), 
and 4--6 (below) days after i.p. injection of 0.75 mg of alum-predpitated ovalbumin, x, con- 
trols treated with PBS; O, CoF-treated mice; T, i.p. injection; and m, time during which 
serum C3 was <5% of normal  in CoF-treated  mice. 140  ROLE  OF  COMPLEMENT IN  INDUCTION OF  ANTIBODY RESPONSE 
phagocytosed (47). Also passively administered IgM antibody, as opposed to 
IgG antibody, can enhance active antibody production in vivo to the specific 
antigen (48). 
Such a concept implies that fixed C3 provides a nonspecific "amplification" 
mechanism  facilitating T-B  cooperation by increasing  the likelihood of rare 
specific B cells encountering their appropriate antigen. On the other hand when 
cells are aggregated only by C3, without any specific antigen-receptor binding, 
this would be transient. The action of the C3b inactivator on fixed C3 inhibits its 
adherence to macrophages (49), and binding to the B-cell C3 receptor is also a 
reversible process  (50).  The  recent  observation  of spontaneously  reversible, 
complement-mediated,  C3-dependent mixed adherence of macrophages,  lym- 
phocytes, and other cells in vitro shows that this model is feasible (51). 
An alternative recent hypothesis is that C3 binding to B-cell C3 receptors con- 
stitutes an obligatory second signal for triggering which B cells must receive in 
addition to specific recognition of T-dependent or T-independent antigens (52, 
53). It has also been suggested that the interaction of "activated" C3 with B 
cells is mitogenic per se (52, 53). Direct testing has, however, demonstrated the 
complement independence of B-cell triggering by mitogens (54). Furthermore, 
the present in vivo results and analogous in vitro observations (13) provide no 
evidence for a  connection between the complement system and antibody re- 
sponses to thymus-independent antigens. 
SUMMARY 
In an in vivo study in mice, suppression by the C3-cleaving protein of cobra 
venom (CoF), and other C3-reactive agents (zymosan, aggregated IgG, anti-C3 
antibodies, and type In  pneumococcal polysaccharide) of the thymus-depend- 
ent antibody responses to sheep erythrocytes, ovalbumin, and human IgG was 
demonstrated.  The  thymus-independent  antibody  response  to  polyvinyl- 
pyrrolidone was however unaffected by CoF. 
These and other published observations suggest that there may be a require- 
ment  for functional  C3  in  induction  of thymus-dependent but  not  thymus- 
independent antibody production. A model for the role of C3 in lymphocyte 
cooperation is proposed based on these data analyzed in the light  of existing 
knowledge of this process. It is postulated that fixed C3 interacting with macro- 
FIG. 9. Effect of CoF on the antibody response  to HGG. CoF was given  to different groups 
of mice so as to produce maximal depletion of circulating C3 between 0-2 (above) and 2-4 
(below) days after subcutaneous  injection of 100 #g of HGG emulsified  in incomplete  adjuvant. 
On day 2 and day II 100 #g of [12~I]HGG  were injected i.p. and its rate of elimination meas- 
ured by whole body counting. Each point represents the geometric mean with 95% con- 
fidence limits, of all the animals in each group. ×, controls treated with PBS; O, CoF-treated 
mice;  T, i.p. injection; and m, time during which serum C3 was <(5% of normal in CoP- 
treated mice. SO, 
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phage and B-cell C3 receptors might enhance or facilitate T-dependent presen- 
tation of antigen to B cells. 
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